Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome.

Microparticles are membrane vesicles that are released during cell activation and apoptosis. Elevated levels of microparticles occur in many cardiovascular diseases; therefore, we characterized circulating microparticles from both metabolic syndrome (MS) patients and healthy patients. We evaluated microparticle effects on endothelial function; however, links between circulating microparticles and endothelial dysfunction have not yet been demonstrated. Circulating microparticles and their cellular origins were examined by flow cytometry of blood samples from patients and healthy subjects. Microparticles were used either to treat human endothelial cells in vitro or to assess endothelium function in mice after intravenous injection. MS patients had increased circulating levels of microparticles compared with healthy patients, including microparticles from platelet, endothelial, erythrocyte, and procoagulant origins. In vitro treatment of endothelial cells with microparticles from MS patients reduced both nitric oxide (NO) and superoxide anion production, resulting in protein tyrosine nitration. These effects were associated with enhanced phosphorylation of endothelial NO synthase at the site of inhibition. The reduction of O2(-) was linked to both reduced expression of p47 phox of NADPH oxidase and overexpression of extracellular superoxide dismutase. The decrease in NO production was triggered by nonplatelet-derived microparticles. In vivo injection of MS microparticles into mice impaired endothelium-dependent relaxation and decreased endothelial NO synthase expression. These data provide evidence that circulating microparticles from MS patients influence endothelial dysfunction.

[1]  S. Grundy,et al.  The metabolic syndrome. , 2008, Endocrine reviews.

[2]  R. Andriantsitohaina,et al.  Rosiglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, Prevents Microparticle-Induced Vascular Hyporeactivity through the Regulation of Proinflammatory Proteins , 2008, Journal of Pharmacology and Experimental Therapeutics.

[3]  V. Richard,et al.  Sonic hedgehog carried by microparticles corrects endothelial injury through nitric oxide release , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  S. N. Murthy,et al.  CARDIOVASCULAR EFFECTS OF PEROXYNITRITE , 2007, Clinical and experimental pharmacology & physiology.

[5]  Giorgio Sesti,et al.  Pathophysiology of insulin resistance. , 2006, Best practice & research. Clinical endocrinology & metabolism.

[6]  A. Simon,et al.  Circulating Leukocyte-Derived Microparticles Predict Subclinical Atherosclerosis Burden in Asymptomatic Subjects , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[7]  K. Pritchard,et al.  ENDOTHELIUM-DERIVED MICROPARTICLES INDUCE ENDOTHELIAL DYSFUNCTION AND ACUTE LUNG INJURY , 2006, Shock.

[8]  R. Andriantsitohaina,et al.  Shed membrane particles from preeclamptic women generate vascular wall inflammation and blunt vascular contractility. , 2006, The American journal of pathology.

[9]  G. Watts,et al.  General Practice — Review , 2022 .

[10]  D. Giugliano,et al.  Endothelial microparticles correlate with endothelial dysfunction in obese women. , 2006, The Journal of clinical endocrinology and metabolism.

[11]  R. Andriantsitohaina,et al.  Origin and biological significance of shed-membrane microparticles. , 2006, Endocrine, metabolic & immune disorders drug targets.

[12]  L. Horstman,et al.  Endothelial microparticles and platelet and leukocyte activation in patients with the metabolic syndrome. , 2006, The American journal of cardiology.

[13]  B. Goichot,et al.  Circulating procoagulant microparticles in obesity. , 2006, Diabetes & metabolism.

[14]  J. Shaw,et al.  How to best define the metabolic syndrome , 2006, Annals of medicine.

[15]  R. D'Agostino,et al.  Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus , 2005, Circulation.

[16]  Chantal M Boulanger,et al.  Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. , 2005, Journal of the American Society of Nephrology : JASN.

[17]  E. Ford,et al.  Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. , 2005, Diabetes care.

[18]  L. Horstman,et al.  Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. , 2005, Journal of the American College of Cardiology.

[19]  J. Freyssinet,et al.  Circulating Cell-Derived Microparticles in Crohn’s Disease , 2005, Digestive Diseases and Sciences.

[20]  R. Andriantsitohaina,et al.  Shed membrane microparticles from circulating and vascular cells in regulating vascular function. , 2005, American journal of physiology. Heart and circulatory physiology.

[21]  J. Freyssinet,et al.  Membrane microparticles: two sides of the coin. , 2005, Physiology.

[22]  H. Minuk,et al.  Metabolic syndrome. , 2005, Journal of insurance medicine.

[23]  W. Jy,et al.  Elevated plasma endothelial microparticles: preeclampsia versus gestational hypertension. , 2004, American journal of obstetrics and gynecology.

[24]  Nathan D. Wong,et al.  Impact of the Metabolic Syndrome on Mortality From Coronary Heart Disease, Cardiovascular Disease, and All Causes in United States Adults , 2004, Circulation.

[25]  M. Goligorsky,et al.  Endothelium-derived microparticles impair endothelial function in vitro. , 2004, American journal of physiology. Heart and circulatory physiology.

[26]  T. Shimazu,et al.  Enhanced production of endothelial microparticles with increased binding to leukocytes in patients with severe systemic inflammatory response syndrome. , 2004, The Journal of trauma.

[27]  F. Dignat-George,et al.  Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome , 2004, Thrombosis and Haemostasis.

[28]  R. Nieuwland,et al.  Elevated Numbers of Tissue-Factor Exposing Microparticles Correlate With Components of the Metabolic Syndrome in Uncomplicated Type 2 Diabetes Mellitus , 2002, Circulation.

[29]  Patrice Darmon,et al.  Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. , 2002, Diabetes.

[30]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[31]  J. Shaw,et al.  Global and societal implications of the diabetes epidemic , 2001, Nature.

[32]  S. S. Lee,et al.  Role of heme oxygenase-carbon monoxide pathway in pathogenesis of cirrhotic cardiomyopathy in the rat. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[33]  R. Moreau,et al.  Changes in protein kinase C isoforms in association with vascular hyporeactivity in cirrhotic rat aortas. , 2000, Gastroenterology.

[34]  J. Freyssinet,et al.  Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. , 2000, Circulation.

[35]  R. Westendorp,et al.  Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. , 2000, Blood.

[36]  M. Mesri,et al.  Leukocyte Microparticles Stimulate Endothelial Cell Cytokine Release and Tissue Factor Induction in a JNK1 Signaling Pathway* , 1999, The Journal of Biological Chemistry.

[37]  G. FitzGerald,et al.  Modulation of monocyte-endothelial cell interactions by platelet microparticles. , 1998, The Journal of clinical investigation.

[38]  G. FitzGerald,et al.  Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. , 1997, The Journal of clinical investigation.

[39]  H. Häring,et al.  [Pathophysiology of insulin resistance]. , 1995, Herz.